Abstract
In Mexico, obesity is the main public health concern and obesity-related conditions represent a very high costs for the Mexican public health system. Liraglutide 3mg is associated with significant and sustained weight loss and improves related complications. The objective of this study is to determine the cost-effectiveness of Liraglutide 3.0mg vs orlistat and no-treatment in Mexico.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
